英國的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗，免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗

英國的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗，免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗 是由出版商GlobalData在2011年12月所出版的。 這份英文市場調查報告書包含Pages: 247 價格從美金2500起跳。

簡介

本報告提供英國的體外診斷市場主要的資料和市場區隔及不同分類的收益，企業佔有率，流通佔有率等調查結果，為您概述為以下內容。

1 目錄

1 目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2 簡介

• 2.1 關於本報告

3 體外診斷 - 英國

• 3.1 體外診斷, 市場區分
• 3.2 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 3.3 體外診斷 市場, 英國, 綜合收益 ($m)
• 3.4 體外診斷 市場, 英國, 各分類收益貢獻度 (%)
• 3.5 體外診斷, 英國, 企業佔有率

4 臨床化學檢驗 - 英國

• 4.1 臨床化學檢驗, 市場區分
• 4.2 臨床化學檢驗 市場, 英國, 綜合收益 ($m)
• 4.3 臨床化學檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 4.4 臨床化學檢驗 整體收益 (實際成果及預測)
• 4.4.1 臨床化學分析設備 收益 (實際成果及預測)
• 4.4.2 尿液檢查 收益 (實際成果及預測)
• 4.5 臨床化學檢驗 流通佔有率
• 4.6 臨床化學檢驗, 英國, 企業佔有率

5 遺傳基因檢驗 - 英國

• 5.1 遺傳基因檢驗, 市場區分
• 5.2 遺傳基因檢驗 市場, 英國, 綜合收益 ($m)
• 5.3 遺傳基因檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 5.4 遺傳基因檢驗 整體收益 (實際成果及預測)
• 5.5 遺傳基因檢驗 流通佔有率
• 5.6 遺傳基因檢驗, 英國, 企業佔有率

6 血液檢驗 - 英國

• 6.1 血液檢驗, 市場區分
• 6.2 血液檢驗 市場, 英國, 綜合收益 ($m)
• 6.3 血液檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 6.4 血液檢驗 整體收益 (實際成果及預測)
• 6.4.1 血液分析試劑 收益 (實際成果及預測)
• 6.4.2 免疫血液學檢查 收益 (實際成果及預測)
• 6.4.3 血液凝固檢查 收益 (實際成果及預測)
• 6.4.4 簡易血液檢驗 收益 (實際成果及預測)
• 6.4.5 血球計數器 收益 (實際成果及預測)
• 6.5 血液檢驗 流通佔有率
• 6.6 血液檢驗, 英國, 企業佔有率

7 組織/細胞檢驗 - 英國

• 7.1 組織/細胞檢驗, 市場區分
• 7.2 組織/細胞檢驗 市場, 英國, 綜合收益 ($m)
• 7.3 組織/細胞檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 7.4 組織/細胞檢驗 整體收益 (實際成果及預測)
• 7.5 組織/細胞檢驗 流通佔有率
• 7.6 組織/細胞檢驗, 英國, 企業佔有率

8 免疫化學檢查 - 英國

• 8.1 免疫化學檢查 市場, 英國, 綜合收益 ($m)
• 8.2 免疫化學檢查 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 8.3 免疫化學檢查 整體收益 (實際成果及預測)
• 8.3.1 疾病專一 免疫化學檢查 收益 (實際成果及預測)
• 8.3.2 藥物濫用檢測 / 藥毒物檢驗 收益 (實際成果及預測)
• 8.3.3 內分泌檢查 收益 (實際成果及預測)
• 8.3.4 藥物治療監測 收益 (實際成果及預測)
• 8.3.5 免疫化學分析儀 收益 (實際成果及預測)
• 8.4 免疫化學檢查 流通佔有率
• 8.5 免疫化學檢查, 英國, 企業佔有率

9 感染/免疫疾病檢驗 - 英國

• 9.1 感染/免疫疾病檢驗, 市場區分
• 9.2 感染/免疫疾病檢驗 市場, 英國, 綜合收益 ($m)
• 9.3 感染/免疫疾病檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 9.4 感染/免疫疾病檢驗 整體收益 (實際成果及預測)
• 9.5 感染/免疫疾病檢驗 流通佔有率
• 9.6 感染/免疫疾病檢驗, 英國, 企業佔有率

10 微生物學培養檢驗 - 英國

• 10.1 微生物學培養檢驗, 市場區分
• 10.2 微生物學培養檢驗 市場, 英國, 綜合收益 ($m)
• 10.3 微生物學培養檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 10.4 微生物學培養檢驗 整體收益 (實際成果及預測)
• 10.4.1 微生物檢驗設備 收益 (實際成果及預測)
• 10.5 微生物學培養檢驗 流通佔有率
• 10.6 微生物學培養檢驗, 英國, 企業佔有率

11 主要企業概要 - 英國 體外診斷 市場

• 11.1 Siemens Healthcare
• 11.1.1 企業概要
• 11.1.2 市場佔有率 - 英國 體外診斷 市場
• 11.2 F. Hoffmann-La Roche Ltd.
• 11.2.1 企業概要
• 11.2.2 市場佔有率 - 英國 體外診斷 市場
• 11.3 Abbott Laboratories
• 11.3.1 企業概要
• 11.3.2 市場佔有率 - 英國 體外診斷 市場
• 11.4 Beckman Coulter, Inc.
• 11.4.1 企業概要
• 11.4.2 市場佔有率 - 英國 體外診斷 市場
• 11.5 Sysmex Corporation
• 11.5.1 企業概要
• 11.5.2 市場佔有率 - 英國 體外診斷 市場
• 11.6 Ortho-Clinical Diagnostics Inc.
• 11.6.1 企業概要
• 11.6.2 市場佔有率 - 英國 體外診斷 市場
• 11.7 bioMerieux S.A.
• 11.7.1 企業概要
• 11.8 Bio-Rad Laboratories, Inc.
• 11.8.1 企業概要
• 11.9 Becton, Dickinson and Company
• 11.9.1 企業概要
• 11.10 Alere Inc.
• 11.10.1 企業概要
• 11.11 Phadia AB
• 11.11.1 企業概要
• 11.12 DiaSorin S.p.A
• 11.12.1 企業概要
• 11.13 Qiagen N.V.
• 11.13.1 企業概要
• 11.14 Gen-Probe Incorporated
• 11.14.1 企業概要
• 11.15 The Elitech Group
• 11.15.1 企業概要
• 11.16 Atlas Medical
• 11.16.1 企業概要
• 11.17 Thermo Fisher Scientific Inc.
• 11.17.1 企業概要
• 11.18 堀場製作所
• 11.18.1 企業概要
• 11.19 PerkinElmer, Inc.
• 11.19.1 企業概要
• 11.20 Hologic, Inc.
• 11.20.1 企業概要
• 11.21 DIAGNOSTICA STAGO, Inc.
• 11.21.1 企業概要
• 11.22 Life Technologies Corporation
• 11.22.1 企業概要

12 體外診斷 市場 開發中產品

• 12.1 臨床化學檢驗 市場 開發中產品
• 12.2 免疫化學檢查 市場 開發中產品
• 12.3 血液檢驗 市場 開發中產品
• 12.4 感染/免疫疾病檢驗 市場 開發中產品
• 12.5 微生物學培養檢驗 市場 開發中產品
• 12.6 組織/細胞檢驗 市場 開發中產品
• 12.7 遺傳基因檢驗 市場 開發中產品

13 財務交易展望

• 13.1 合併
• 13.2 收購
• 13.3 合作

14 最新趨勢

• 14.1 策略及產業計畫
• 14.2 法律行為及法規
• 14.3 政府及公益相關
• 14.4 產品資訊

15 附錄

• 15.1 調查對象的市場定義
• 15.1.1 體外診斷
• 15.2 調查方法
• 15.3 二級研究
• 15.4 主要研究
• 15.5 資料的模式化
• 15.6 預測
• 15.7 專門委員會
• 15.8 GlobalData 諮詢服務
• 15.9 貨幣換算
• 15.10 諮詢方式
• 15.11 免責聲明

表格一覽

1.1 表格一覽

• 表格 1: 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 2: 體外診斷 市場, 英國, 各分類收益貢獻度 (%)
• 表格 3: 體外診斷, 英國, 分類間分析, 實際成果及預測
• 表格 4: 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 5: 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 6: 體外診斷, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 7: 臨床化學檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 8: 臨床化學檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 9: 臨床化學檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 10: 臨床化學分析設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 11: 臨床化學分析設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 12: 尿液檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 13: 尿液檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 14: 臨床化學檢驗, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 15: 臨床化學檢驗, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 16: 遺傳基因檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 17: 遺傳基因檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 18: 遺傳基因檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 19: 遺傳基因檢驗, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 20: 遺傳基因檢驗, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 21: 血液檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 22: 血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 23: 血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 24: 血液分析試劑, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 25: 血液分析試劑, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 26: 免疫血液學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 27: 免疫血液學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 28: 血液凝固檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 29: 血液凝固檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 30: 簡易血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 31: 簡易血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 32: 血球計數器, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 33: 血球計數器, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 34: 血液檢驗, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 35: 血液檢驗, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 36: 組織/細胞檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 37: 組織/細胞檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 38: 組織/細胞檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 39: 組織/細胞檢驗, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 40: 組織/細胞檢驗, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 41: 免疫化學檢查 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 42: 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 43: 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 44: 疾病專一 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 45: 疾病專一 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 46: 藥物濫用檢測 / 藥毒物檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 47: 藥物濫用檢測 / 藥毒物檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 48: 內分泌檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 49: 內分泌檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 50: 藥物治療監測, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 51: 藥物治療監測, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 52: 免疫化學分析儀, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 53: 免疫化學分析儀, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 54: 免疫化學檢查, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 55: 免疫化學檢查, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 56: 感染/免疫疾病檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 57: 感染/免疫疾病檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 58: 感染/免疫疾病檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 59: 感染/免疫疾病檢驗, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 60: 感染/免疫疾病檢驗, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 61: 微生物學培養檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 表格 62: 微生物學培養檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 表格 63: 微生物學培養檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 表格 64: 微生物檢驗設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 表格 65: 微生物檢驗設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 表格 66: 微生物學培養檢驗, 英國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 67: 微生物學培養檢驗, 英國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 68: 臨床化學檢驗 市場 開發中產品
• 表格 69: 免疫化學檢查 市場 開發中產品
• 表格 70: 血液檢驗 市場 開發中產品
• 表格 71: 感染/免疫疾病檢驗 市場 開發中產品
• 表格 72: 微生物學培養檢驗 市場 開發中產品
• 表格 73: 組織/細胞檢驗 市場 開發中產品
• 表格 74: 遺傳基因檢驗 市場 開發中產品
• 表格 75∼96: 體外診斷市場, 英國, 交易內容詳細內容
• 表格 97: 美金V.S.該地貨幣, 英國, 平均實質匯率

圖表一覽

1.2 圖表一覽

• 圖 1: 體外診斷, 市場區分
• 圖 2: 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 3: 體外診斷 市場, 英國, 綜合收益 ($m)
• 圖 4: 體外診斷 市場, 英國, 各分類收益貢獻度 (%)
• 圖 5: 體外診斷, 英國, 分類間分析, 實際成果及預測
• 圖 6: 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 7: 體外診斷, 英國, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 8: 體外診斷, 英國, 企業佔有率 (%)
• 圖 9: 臨床化學檢驗, 市場區分
• 圖 10: 臨床化學檢驗 市場, 英國, 綜合收益 ($m)
• 圖 11: 臨床化學檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 12: 臨床化學檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 13: 臨床化學檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 14: 臨床化學分析設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 15: 臨床化學分析設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 16: 尿液檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 17: 尿液檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 18: 臨床化學檢驗, 英國, 企業佔有率 (%)
• 圖 19: 遺傳基因檢驗, 市場區分
• 圖 20: 遺傳基因檢驗 市場, 英國, 綜合收益 ($m)
• 圖 21: 遺傳基因檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 22: 遺傳基因檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 23: 遺傳基因檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 24: 遺傳基因檢驗, 英國, 企業佔有率 (%)
• 圖 25: 血液檢驗, 市場區分
• 圖 26: 血液檢驗 市場, 英國, 綜合收益 ($m)
• 圖 27: 血液檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 28: 血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 29: 血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 30: 血液分析試劑, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 31: 血液分析試劑, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 32: 免疫血液學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 33: 免疫血液學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 34: 血液凝固檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 35: 血液凝固檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 36: 簡易血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 37: 簡易血液檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 38: 血球計數器, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 39: 血球計數器, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 40: 血液檢驗, 英國, 企業佔有率 (%)
• 圖 41: 組織/細胞檢驗, 市場區分
• 圖 42: 組織/細胞檢驗 市場, 英國, 綜合收益 ($m)
• 圖 43: 組織/細胞檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 44: 組織/細胞檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 45: 組織/細胞檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 46: 組織/細胞檢驗, 英國, 企業佔有率 (%)
• 圖 47: 免疫化學檢查 市場, 英國, 綜合收益 ($m)
• 圖 48: 免疫化學檢查 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 49: 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 50: 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 51: 疾病專一 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 52: 疾病專一 免疫化學檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 53: 藥物濫用檢測 / 藥毒物檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 54: 藥物濫用檢測 / 藥毒物檢驗, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 55: 內分泌檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 56: 內分泌檢查, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 57: 藥物治療監測, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 58: 藥物治療監測, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 59: 免疫化學分析儀, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 60: 免疫化學分析儀, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 61: 免疫化學檢查, 英國, 企業佔有率 (%)
• 圖 62: 感染/免疫疾病檢驗, 市場區分
• 圖 63: 感染/免疫疾病檢驗 市場, 英國, 綜合收益 ($m)
• 圖 64: 感染/免疫疾病檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 65: 感染/免疫疾病檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 66: 感染/免疫疾病檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 67: 感染/免疫疾病檢驗, 英國, 企業佔有率 (%)
• 圖 68: 微生物學培養檢驗, 市場區分
• 圖 69: 微生物學培養檢驗 市場, 英國, 綜合收益 ($m)
• 圖 70: 微生物學培養檢驗 市場, 英國, 不同市場區隔收益貢獻度 (%)
• 圖 71: 微生物學培養檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔, 實際成果
• 圖 72: 微生物學培養檢驗, 英國, 收益 ($m), USD 以實額為基礎 不同市場區隔，預測
• 圖 73: 微生物檢驗設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔, 實際成果
• 圖 74: 微生物檢驗設備, 英國, 收益 ($m), USD 以實額為基礎 各子市場區隔，預測
• 圖 75: 微生物學培養檢驗, 英國, 企業佔有率 (%)
• 圖 76: Siemens Healthcare, 企業佔有率 (%),英國 體外診斷 市場
• 圖 77: F. Hoffmann-La Roche Ltd., 企業佔有率 (%),英國 體外診斷 市場
• 圖 78: Abbott Laboratories, 企業佔有率 (%),英國 體外診斷 市場
• 圖 79: Beckman Coulter, Inc., 企業佔有率 (%),英國 體外診斷 市場
• 圖 80: Sysmex Corporation, 企業佔有率 (%),英國 體外診斷 市場
• 圖 81: Ortho-Clinical Diagnostics Inc., 企業佔有率 (%),英國 體外診斷 市場

目錄

Abstract

United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "United Kingdom In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the United Kingdom In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
• Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
• 2010 company shares and distribution shares data for each of the seven market categories.
• Global corporate-level profiles of key companies operating within the United Kingdom In Vitro Diagnosticsmarket.
• Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Beckman Coulter, Inc., Sysmex Corporation, Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the United Kingdom In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 11
• 1.2 List of Figures 14

2 Introduction 17

• 2.1 What is This Report About? 17

3 In Vitro Diagnostics In United Kingdom 18

• 3.1 In Vitro Diagnostics, Market Segmentation 18
• 3.2 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 19
• 3.3 In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2010 21
• 3.4 In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2010 22
• 3.5 In Vitro Diagnostics, United Kingdom, Company share (2009-2010) 29

4 Clinical Chemistry In United Kingdom 31

• 4.1 Clinical Chemistry, Market Segmentation 31
• 4.2 Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2010 32
• 4.3 Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2010 33
• 4.4 Clinical Chemistry Overall Revenue (2003-2017) 34
• 4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 38
• 4.4.2 Urine Analysis Revenue (2003-2017) 42
• 4.5 Clinical Chemistry Distribution Share (2009-2010) 46
• 4.6 Clinical Chemistry, United Kingdom, Company share (2009-2010) 47

5 Genetic Testing In United Kingdom 49

• 5.1 Genetic Testing, Market Segmentation 49
• 5.2 Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2010 50
• 5.3 Genetic Testing Market, United Kingdom, Segment Contribution (%), 2010 51
• 5.4 Genetic Testing Overall Revenue (2003-2017) 52
• 5.5 Genetic Testing Distribution Share (2009-2010) 56
• 5.6 Genetic Testing, United Kingdom, Company share (2009-2010) 57

6 Haematology In United Kingdom 59

• 6.1 Haematology, Market Segmentation 59
• 6.2 Haematology Market, United Kingdom, Revenue Mix ($m), 2010 60
• 6.3 Haematology Market, United Kingdom, Segment Contribution (%), 2010 61
• 6.4 Haematology Overall Revenue (2003-2017) 62
• 6.4.1 Haematology Reagents Revenue (2003-2017) 66
• 6.4.2 Immunohaematology Revenue (2003-2017) 70
• 6.4.3 Haemostasis Revenue (2003-2017) 74
• 6.4.4 Haematology Rapid Tests Revenue (2003-2017) 78
• 6.4.5 Haematology Cell Counters Revenue (2003-2017) 82
• 6.5 Haematology Distribution Share (2009-2010) 86
• 6.6 Haematology, United Kingdom, Company share (2009-2010) 87

7 Histology And Cytology In United Kingdom 89

• 7.1 Histology And Cytology, Market Segmentation 89
• 7.2 Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2010 90
• 7.3 Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2010 91
• 7.4 Histology And Cytology Overall Revenue (2003-2017) 92
• 7.5 Histology And Cytology Distribution Share (2009-2010) 96
• 7.6 Histology And Cytology, United Kingdom, Company share (2009-2010) 97

8 Immuno Chemistry In United Kingdom 99

• 8.1 Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2010 99
• 8.2 Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2010 100
• 8.3 Immuno Chemistry Overall Revenue (2003-2017) 101
• 8.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 105
• 8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 109
• 8.3.3 Endocrinology Tests Revenue (2003-2017) 113
• 8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 117
• 8.3.5 Immunochemistry Analyzers Revenue (2003-2017) 121
• 8.4 Immuno Chemistry Distribution Share (2009-2010) 125
• 8.5 Immuno Chemistry, United Kingdom, Company share (2009-2010) 126

9 Infectious Immunology In United Kingdom 128

• 9.1 Infectious Immunology, Market Segmentation 128
• 9.2 Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2010 129
• 9.3 Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2010 130
• 9.4 Infectious Immunology Overall Revenue (2003-2017) 131
• 9.5 Infectious Immunology Distribution Share (2009-2010) 135
• 9.6 Infectious Immunology, United Kingdom, Company share (2009-2010) 136

10 Microbiology Culture In United Kingdom 138

• 10.1 Microbiology Culture, Market Segmentation 138
• 10.2 Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2010 139
• 10.3 Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2010 140
• 10.4 Microbiology Culture Overall Revenue (2003-2017) 141
• 10.4.1 Microbiology Analyzers Revenue (2003-2017) 145
• 10.5 Microbiology Culture Distribution Share (2009-2010) 149
• 10.6 Microbiology Culture, United Kingdom, Company share (2009-2010) 150

11 Overview of Key Companies in United Kingdom In Vitro Diagnostics Market 152

• 11.1 Siemens Healthcare 152
• 11.1.1 Company Overview 152
• 11.1.2 Share in the United Kingdom In Vitro Diagnostics Market 152
• 11.2 F. Hoffmann-La Roche Ltd. 153
• 11.2.1 Company Overview 153
• 11.2.2 Share in the United Kingdom In Vitro Diagnostics Market 153
• 11.3 Abbott Laboratories 154
• 11.3.1 Company Overview 154
• 11.3.2 Share in the United Kingdom In Vitro Diagnostics Market 154
• 11.4 Beckman Coulter, Inc. 155
• 11.4.1 Company Overview 155
• 11.4.2 Share in the United Kingdom In Vitro Diagnostics Market 155
• 11.5 Sysmex Corporation 156
• 11.5.1 Company Overview 156
• 11.5.2 Share in the United Kingdom In Vitro Diagnostics Market 156
• 11.6 Ortho-Clinical Diagnostics Inc. 157
• 11.6.1 Company Overview 157
• 11.6.2 Share in the United Kingdom In Vitro Diagnostics Market 157
• 11.7 bioMerieux S.A. 158
• 11.7.1 Company Overview 158
• 11.8 Bio-Rad Laboratories, Inc. 158
• 11.8.1 Company Overview 158
• 11.9 Becton, Dickinson and Company 158
• 11.9.1 Company Overview 158
• 11.10 Alere Inc. 159
• 11.10.1 Company Overview 159
• 11.11 Phadia AB 159
• 11.11.1 Company Overview 159
• 11.12 DiaSorin S.p.A 159
• 11.12.1 Company Overview 159
• 11.13 Qiagen N.V. 160
• 11.13.1 Company Overview 160
• 11.14 Gen-Probe Incorporated 160
• 11.14.1 Company Overview 160
• 11.15 The Elitech Group 160
• 11.15.1 Company Overview 160
• 11.16 Atlas Medical 161
• 11.16.1 Company Overview 161
• 11.17 Thermo Fisher Scientific Inc. 161
• 11.17.1 Company Overview 161
• 11.18 HORIBA, Ltd. 161
• 11.18.1 Company Overview 161
• 11.19 PerkinElmer, Inc. 162
• 11.19.1 Company Overview 162
• 11.20 Hologic, Inc. 162
• 11.20.1 Company Overview 162
• 11.21 DIAGNOSTICA STAGO, Inc. 163
• 11.21.1 Company Overview 163
• 11.22 Life Technologies Corporation 163
• 11.22.1 Company Overview 163

12 In Vitro Diagnostics Market Pipeline Products 164

• 12.1 Clinical Chemisty Market Pipeline Products 164
• 12.2 Immuno Chemistry Market Pipeline Products 167
• 12.3 Haematology Market Pipeline Products 170
• 12.4 Infectious Immunology Market Pipeline Products 172
• 12.5 Microbiology Culture Market Pipeline Products 175
• 12.6 Histology And Cytology Market Pipeline Products 176
• 12.7 Genetic Testing Market Pipeline Products 177

13 Financial Deals Landscape 180

• 13.1 Merger 180
• 13.1.1 Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM 180
• 13.2 Acquisition 181
• 13.2.1 Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million 181
• 13.2.2 Lab21 Acquires Myconostica 183
• 13.2.3 Techne Acquires Boston Biochem And Boston Biochem 184
• 13.2.4 Agilent Technologies Acquires Lab901 185
• 13.2.5 Imperial Innovations Acquires Minority Stake In Molecular Vision 187
• 13.2.6 Lab21 Acquires Microgen Bioproducts 188
• 13.3 Partnerships 189
• 13.3.1 Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 189
• 13.3.2 Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 190
• 13.3.3 Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia 191
• 13.3.4 Horizon Discovery Enters Into Co-Development Agreement With Promega 192
• 13.3.5 Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 193
• 13.3.6 Generation Scotland Enters Into Co-Development Agreement With Arrayjet 194
• 13.3.7 Almac Group Enters Into Research Agreement With Queen's University Belfast 195
• 13.3.8 Lumora Enters Into Licensing Agreement With 3M 196
• 13.3.9 BD Diagnostics Enters Into Co-Development Agreement With Lab21 197
• 13.3.10 Hycor Biomedical Signs Licensing Agreement With Axis-Shield 198
• 13.3.11 Proteome Sciences Enters Into Collaboration With Buck Institute 199
• 13.3.12 Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center 200
• 13.3.13 Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 201
• 13.3.14 ResearchDx Enters Into Partnership With CompanDX 202
• 13.3.15 Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 203

14 Recent Developments 204

• 14.1 Strategy and Business Planning 204
• 14.1.1 Sep 15, 2011: GE Healthcare To Invest $1 Billion in New Oncology R&D Solutions 204
• 14.1.2 Jul 21, 2011: Oxford Nanopore Expands Oxford Headquarters And Opens New Informatics Outstation In Cambridge, UK 205
• 14.1.3 Jun 28, 2011: Thermo Fisher And UK HPA Collaborate To Identify Toxicity Of New E. coli Strain 205
• 14.1.4 May 20, 2011: Almac Opens New North American Headquarters 206
• 14.1.5 May 19, 2011: Millipore Expands BioPharma CRO Services In Europe 206
• 14.1.6 Jan 20, 2011: Waters To Build New Mass Spectrometry Headquarters Near Manchester, UK 206
• 14.2 Legal and Regulatory 207
• 14.2.1 Nov 15, 2011: MonoSol Rx And Midatech Receive Authorization To Conduct Phase I Human Trials For Transbuccal Insulin PharmFilm 207
• 14.2.2 Aug 13, 2011: GE Healthcare And Bio-Rad Reach Settlement In Label-Free Detection Lawsuit 208
• 14.2.3 Jun 17, 2011: 3M Accused Of Breaking Promise To Market Life-Saving Medical Device Invented By British Government 208
• 14.2.4 Jan 10, 2011: Astellas To Review Strategic Business Alternatives For Prosidion Subsidiary 209
• 14.3 Government and Public Interest 209
• 14.3.1 Dec 19, 2011: NHS Publishes Implementation Guidelines For Source BioScience's Automated Cervical Cancer Screening Technology 209
• 14.3.2 Aug 22, 2011: Researchers Developing Blood Test To Improve Diagnosis Of Sickle Cell Disease In Babies: Action Medical 210
• 14.3.3 Jul 15, 2011: 'Swine Flu' Breath Test Could Reduce Future Vaccination Shortages, Research Suggests 211
• 14.3.4 Jul 12, 2011: CXR Biosciences And Taconic Announce Publication Of Drug-drug Interaction Study By Molecular Pharmacology Journal 212
• 14.3.5 Jun 27, 2011: University Of Leicester Study Into Use Of Blood Markers To Detect And Monitor Breast Cancer 212
• 14.3.6 Mar 25, 2011: NICE Pilot Diagnostics Project Points Way Forward For Evaluation Of Diagnostic Technologies 213
• 14.3.7 Mar 24, 2011: Oxford Immunotec: UK's NICE Recommend Replacing Mantoux With TB Blood Tests For Key Patient Groups 214
• 14.3.8 Mar 17, 2011: Birmingham Scientists Create Test To Track Global Spread Of Antibiotic Resistance 214
• 14.3.9 Mar 02, 2011: New Way To Detect Prostate Cancer With New Urine Test: University Of Surrey Researchers 215
• 14.3.10 Mar 01, 2011: Gene Test To Predict Nerve Damage From Bone Cancer Treatment: Study 216
• 14.3.11 Feb 22, 2011: Peninsula Medical School Researchers Develop Home Urine Test Which Measures Insulin Production In Diabetes 216
• 14.3.12 Feb 11, 2011: Newcastle University Scientists Identify New Gene Test For Inherited Neuromuscular Disorder 217
• 14.3.13 Feb 09, 2011: Gene Test Could Solve Prostate Cancer Riddle And Spare Thousands From Surgery: UK Study 217
• 14.3.14 Feb 03, 2011: MRC Scientists Develop Blood Test For Variant Creutzfeldt-Jakob Disease 218
• 14.4 Product News 219
• 14.4.1 Dec 06, 2011: Trinity Biotech Receives FDA Approval For Premier Hb9210 219
• 14.4.2 Nov 23, 2011: Randox Toxicology Releases ELISA For Rapid Detection Of Synthetic Cannabinoids And Other Designer Drugs 220
• 14.4.3 Nov 15, 2011: Systagenix To Launch WOUNDCHEK Protease Status 220
• 14.4.4 Nov 09, 2011: Lab21 Announces Positive Results For MycAssayM Aspergillus Assay 221
• 14.4.5 Oct 05, 2011: Epistem Forms Human DNA Identification Collaboration With NPIA 222
• 14.4.6 Sep 01, 2011: CellaVision Delivers 1,000th CellaVision DM analyzer To Southampton General Hospital, England 222
• 14.4.7 Jul 18, 2011: Enigma Completes RANGER Project Based On Enigma ML-Influenza A/B 222
• 14.4.8 Jun 20, 2011: IntegenX Announces Early Access Partnership For RapidHIT 200 Human DNA Identification System 223
• 14.4.9 May 24, 2011: Studies Show Crescendo Bioscience's Vectra DA Can Track Early Response To Rheumatoid Arthritis Therapy And Predict Joint Damage At Molecular Level 224
• 14.4.10 Apr 11, 2011: Enigma Announces Start Of US Clinical Trials For Influenza A/B Detection Assay 226
• 14.4.11 Apr 11, 2011: Enigma Announces Start Of US Clinical Trials For Influenza A/B Detection Assay 226
• 14.4.12 Apr 07, 2011: Myconostica Announces Publication Of Evaluation Of MycAssay Aspergillus Kit Performance 227
• 14.4.13 Apr 04, 2011: Myconostica Announces Publication Of Trial Results With MycAssay Pneumocystis Kit 227
• 14.4.14 Mar 22, 2011: Sphere Medical Receives FDA 510(k) Clearance For IVD-GE02 Blood Analyzer 228
• 14.4.15 Mar 22, 2011: Sphere Medical Receives FDA 510(k) Clearance For IVD-GE02 Blood Analyzer 228
• 14.4.16 Feb 28, 2011: Renishaw Diagnostics Launches RenDx RUO Multiplex Assay System 230
• 14.4.17 Feb 14, 2011: ValiRx Launches Chlamydia SELFCheck Over-The-Counter Health Screening Product 230

15 Appendix 232

• 15.1 Definitions of Markets Covered in the Report 233
• 15.1.1 In Vitro Diagnostics 233
• 15.2 Research Methodology 244
• 15.3 Secondary Research 244
• 15.4 Primary Research 245
• 15.5 Models 245
• 15.6 Forecasts 246
• 15.7 Expert Panels 246
• 15.8 GlobalData Consulting 246
• 15.9 Currency Conversion 247
• 15.10 Contact Us 247
• 15.11 Disclaimer 247

List of Tables

1.1 List of Tables

• Table 1: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 20
• Table 2: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2010 22
• Table 3: In Vitro Diagnostics, United Kingdom, Cross-Category Analysis, 2003-2017 24
• Table 4: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 26
• Table 5: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 28
• Table 6: In Vitro Diagnostics, United Kingdom, Company share by Revenue ($m), USD Actual, 2009-2010 30
• Table 7: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2010 33
• Table 8: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 35
• Table 9: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 37
• Table 10: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 39
• Table 11: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 41
• Table 12: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 43
• Table 13: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 45
• Table 14: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 46
• Table 15: Clinical Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 48
• Table 16: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2010 51
• Table 17: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 53
• Table 18: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 55
• Table 19: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 56
• Table 20: Genetic Testing, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 58
• Table 21: Haematology Market, United Kingdom, Segment Contribution (%), 2010 61
• Table 22: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 63
• Table 23: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 65
• Table 24: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 67
• Table 25: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 69
• Table 26: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 71
• Table 27: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 73
• Table 28: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 75
• Table 29: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 77
• Table 30: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 79
• Table 31: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 81
• Table 32: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 83
• Table 33: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 85
• Table 34: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 86
• Table 35: Haematology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 88
• Table 36: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2010 91
• Table 37: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 93
• Table 38: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 95
• Table 39: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
• Table 40: Histology And Cytology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 98
• Table 41: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2010 100
• Table 42: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 102
• Table 43: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 104
• Table 44: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 106
• Table 45: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 108
• Table 46: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 110
• Table 47: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 112
• Table 48: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114
• Table 49: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116
• Table 50: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 118
• Table 51: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 120
• Table 52: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 122
• Table 53: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 124
• Table 54: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 125
• Table 55: Immuno Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 127
• Table 56: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2010 130
• Table 57: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 132
• Table 58: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 134
• Table 59: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 135
• Table 60: Infectious Immunology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 137
• Table 61: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2010 140
• Table 62: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 142
• Table 63: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 144
• Table 64: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 146
• Table 65: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 148
• Table 66: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 149
• Table 67: Microbiology Culture, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 151
• Table 68: Clinical Chemisty Market Pipeline Products 164
• Table 69: Immuno Chemistry Market Pipeline Products 167
• Table 70: Haematology Market Pipeline Products 170
• Table 71: Infectious Immunology Market Pipeline Products 172
• Table 72: Microbiology Culture Market Pipeline Products 175
• Table 73: Histology And Cytology Market Pipeline Products 176
• Table 74: Genetic Testing Market Pipeline Products 177
• Table 75: Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM 180
• Table 76: Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million 181
• Table 77: Lab21 Acquires Myconostica 183
• Table 78: Techne Acquires Boston Biochem And Boston Biochem 184
• Table 79: Agilent Technologies Acquires Lab901 185
• Table 80: Imperial Innovations Acquires Minority Stake In Molecular Vision 187
• Table 81: Lab21 Acquires Microgen Bioproducts 188
• Table 82: Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 189
• Table 83: Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 190
• Table 84: Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia 191
• Table 85: Horizon Discovery Enters Into Co-Development Agreement With Promega 192
• Table 86: Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 193
• Table 87: Generation Scotland Enters Into Co-Development Agreement With Arrayjet 194
• Table 88: Almac Group Enters Into Research Agreement With Queen's University Belfast 195
• Table 89: Lumora Enters Into Licensing Agreement With 3M 196
• Table 90: BD Diagnostics Enters Into Co-Development Agreement With Lab21 197
• Table 91: Hycor Biomedical Signs Licensing Agreement With Axis-Shield 198
• Table 92: Proteome Sciences Enters Into Collaboration With Buck Institute 199
• Table 93: Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center 200
• Table 94: Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 201
• Table 95: ResearchDx Enters Into Partnership With CompanDX 202
• Table 96: Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 203
• Table 97: USD to Local Currency, United Kingdom, Average Actual Rate 2003-2010 247

List of Figures

1.2 List of Figures

• Figure 1: In Vitro Diagnostics, Market Segmentation 18
• Figure 2: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 19
• Figure 3: In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2010 21
• Figure 4: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2010 22
• Figure 5: In Vitro Diagnostics, United Kingdom, Cross-Category Analysis, 2003-2017 23
• Figure 6: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 25
• Figure 7: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 27
• Figure 8: In Vitro Diagnostics, United Kingdom, Company share (%), 2010 29
• Figure 9: Clinical Chemistry, Market Segmentation 31
• Figure 10: Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2010 32
• Figure 11: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2010 33
• Figure 12: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 34
• Figure 13: Clinical Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 36
• Figure 14: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 38
• Figure 15: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 40
• Figure 16: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 42
• Figure 17: Urine Analysis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 44
• Figure 18: Clinical Chemistry, United Kingdom, Company share (%), 2010 47
• Figure 19: Genetic Testing, Market Segmentation 49
• Figure 20: Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2010 50
• Figure 21: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2010 51
• Figure 22: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 52
• Figure 23: Genetic Testing, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 54
• Figure 24: Genetic Testing, United Kingdom, Company share (%), 2010 57
• Figure 25: Haematology, Market Segmentation 59
• Figure 26: Haematology Market, United Kingdom, Revenue Mix ($m), 2010 60
• Figure 27: Haematology Market, United Kingdom, Segment Contribution (%), 2010 61
• Figure 28: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 62
• Figure 29: Haematology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 64
• Figure 30: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 66
• Figure 31: Haematology Reagents, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 68
• Figure 32: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 70
• Figure 33: Immunohaematology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 72
• Figure 34: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 74
• Figure 35: Haemostasis, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 76
• Figure 36: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 78
• Figure 37: Haematology Rapid Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 80
• Figure 38: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 82
• Figure 39: Haematology Cell Counters, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 84
• Figure 40: Haematology, United Kingdom, Company share (%), 2010 87
• Figure 41: Histology And Cytology, Market Segmentation 89
• Figure 42: Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2010 90
• Figure 43: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2010 91
• Figure 44: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 92
• Figure 45: Histology And Cytology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 94
• Figure 46: Histology And Cytology, United Kingdom, Company share (%), 2010 97
• Figure 47: Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2010 99
• Figure 48: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2010 100
• Figure 49: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 101
• Figure 50: Immuno Chemistry, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 103
• Figure 51: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 105
• Figure 52: Disease Specific Immunochemistry, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 107
• Figure 53: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 109
• Figure 54: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 111
• Figure 55: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 113
• Figure 56: Endocrinology Tests, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 115
• Figure 57: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 117
• Figure 58: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 119
• Figure 59: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 121
• Figure 60: Immunochemistry Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 123
• Figure 61: Immuno Chemistry, United Kingdom, Company share (%), 2010 126
• Figure 62: Infectious Immunology, Market Segmentation 128
• Figure 63: Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2010 129
• Figure 64: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2010 130
• Figure 65: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 131
• Figure 66: Infectious Immunology, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 133
• Figure 67: Infectious Immunology, United Kingdom, Company share (%), 2010 136
• Figure 68: Microbiology Culture, Market Segmentation 138
• Figure 69: Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2010 139
• Figure 70: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2010 140
• Figure 71: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 141
• Figure 72: Microbiology Culture, United Kingdom, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 143
• Figure 73: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 145
• Figure 74: Microbiology Analyzers, United Kingdom, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 147
• Figure 75: Microbiology Culture, United Kingdom, Company share (%), 2010 150
• Figure 76: Siemens Healthcare, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010 152
• Figure 77: F. Hoffmann-La Roche Ltd., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010 153
• Figure 78: Abbott Laboratories, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010 154
• Figure 79: Beckman Coulter, Inc., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010 155
• Figure 80: Sysmex Corporation, Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010 156
• Figure 81: Ortho-Clinical Diagnostics Inc., Company Share (%),United Kingdom In Vitro Diagnostics Market, 2010 157

相關商品

體外診斷設備相關市場調查報告書

全球切片設備市場:開發平台分析，競爭環境，到2018年為止的市場預測
Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
價格 : US $ 3995
出版日期 : 2012年04月

全球分子診斷市場:各國的設施·檢驗數量·銷售額預測
2012 World Molecular Diagnostics Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
價格 : US $ 1850
出版日期 : 2012年04月

全球微生物測試市場展望：成長機會及業務拓展策略
2012 Microbiology Testing Market Outlook: Growth Opportunities and Strategies
價格 : US $ 28700
出版日期 : 2012年04月

GlobalData發行的醫療設備相關市場調查報告書

全球先進型創傷管理市場:開發平台分析，競爭環境，到2018年為止的市場預測

Advanced Wound Management - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

臨床化學:全球性開發平台分析，競爭情形，到2018年為止的市場未來預測

Clinical Chemistry - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

免疫化學分析儀與檢查套件:全球性開發平台分析，競爭情形，到2018年為止的市場未來預測

Immunochemistry Analyzers and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!